"Belgium's Solvay said on Wednesday rival firm Perrigo Israel Pharmaceuticals had applied for approval from U.S. authorities to sell a generic version of Solvay's treatment for testosterone deficiency."
"At the start of this year, the Federal Trade Commission filed a complaint challenging agreements in which Solvay allegedly paid generic drug makers Watson Pharmaceuticals and Par Pharmaceutical Companies to delay generic competition."
"Worldwide sales of Androgel rose by 9 percent to 337 million euros ($475.5 million) last year.
I had no idea that the sales of Testosterone gels were soo high, doesn't sound like Solvay is playing fair when it comes to defending it's market share.
No comments:
Post a Comment